+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1593 Actively Recruiting clinical trials

C

Actively Recruiting

This research aims to evaluate whether taking antipsychotic medication every other day is as effective as the usual daily dosing for people with schizophrenia or related disorders. The study also explores if the alternate day dosing reduces side effects compared to daily treatment. It is a randomized, double-blind trial designed to compare these two dosing schedules over one year. Participants will be randomly assigned to either continue their current daily antipsychotic medication risperidone, olanzapine, or paliperidone or switch to an alternate day dosing schedule. To maintain blinding, active medication and placebo capsules are provided in matching blister packs so participants and staff cannot tell which regimen is assigned. Doses range from 1 mg to 16 mg for risperidone, 5 mg to 20 mg for olanzapine, and 3 mg to 12 mg for paliperidone. Treatment is individualized, and other psychotropic medications can continue if stable. Participants will attend 22 visits over 52 weeks, with visits every two weeks for the first six months and monthly visits for the final six months. Researchers will assess symptom severity and side effects using several scales, including the Brief Psychiatric Rating Scale and multiple symptom and wellbeing questionnaires. The main outcome focuses on clinical deterioration at the start and end of the study. Safety and medication adherence will be closely monitored throughout the trial.

Age: 18Years +All GendersPhase 4
1 location
E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
C

Actively Recruiting

Prostate cancer patients with favorable-risk disease are commonly treated with lengthy courses of image guided radiation therapy IGRT. Researchers are investigating a shorter, more convenient approach by combining one stereotactic ablative body radiotherapy SABR treatment with one high-dose rate HDR brachytherapy treatment guided by MRI. This study aims to assess if this combined approach can maintain good cancer control while reducing side effects, treatment time, and costs. Participants will first undergo imaging and marker placement to prepare for treatment. Then they receive one SABR treatment delivering a high dose to the prostate and seminal vesicles. About one week later, imaging is repeated to plan a single HDR brachytherapy dose targeted to the prostate and visible tumor areas. Both treatments use imaging guidance to accurately deliver radiation. Dosimetric data will be collected during treatment. Patients will be monitored closely from the start of SABR treatment through five years. Assessments include evaluations of urinary, rectal, and sexual function, side effects at multiple time points, blood tests for PSA and testosterone, and quality of life questionnaires. Samples of urine, blood, and biopsy tissue will be collected before and after treatment for further study. This thorough follow-up aims to track safety, side effects, quality of life, and cancer control over time.

All AgesMALEPhase 2Phase 3
1 location
A

Actively Recruiting

Researchers are investigating the effects of deep brain stimulation DBS on brain function using advanced MRI techniques, focusing on patients with various neurological and psychiatric disorders such as Parkinsons disease, essential tremor, dystonia, depression, epilepsy, neuropathic pain, and Alzheimers disease. The study explores how DBS modulates brain circuits and whether functional MRI fMRI can improve clinical programming of DBS. This prospective cohort study aims to enhance understanding of DBS impact on brain anatomy and function in patients who have undergone or will undergo DBS electrode placement. Participants will undergo fMRI scans with DBS devices either turned off or on, including structural MRI scans at 1.5 or 3 Tesla strength and functional MRI scans both at rest and during tasks. The fMRI results will be used to aid clinicians in optimizing DBS programming for individual patients. Safety tests have confirmed that these imaging procedures are safe for patients with DBS implants. The study includes pre-operative patients as well as those with externalized leads or internalized implantable pulse generators. During the study, participants will have brain imaging performed before and after DBS implantation, with evaluations spanning from 3 months prior to 1 year following the implant. Researchers will assess brain areas engaged by DBS, structural and functional connectivity via MRI, and clinical outcomes. This information aims to support post-operative DBS follow-up and improve treatment management. The study involves informed consent and careful monitoring, with the total participation duration extending up to one year after DBS implantation.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.

Age: 18Years +All GendersPhase 3
33 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.

Age: 18Years +All GendersPhase 1Phase 2
82 locations
S

Actively Recruiting

This research aims to find out if intismeran autogene combined with pembrolizumab can stop the growth or spread of advanced melanoma, a type of skin cancer that has spread to other parts of the body and cannot be removed by surgery. The study compares this combination to a placebo with pembrolizumab to see if people live longer without their cancer worsening. Immunotherapy, which helps the immune system fight cancer, is the standard treatment for advanced melanoma. Participants in the study will be randomly assigned to receive either intismeran autogene by intramuscular injection every three weeks for up to nine doses plus pembrolizumab by intravenous infusion every six weeks for up to 17 doses or until the disease progresses or they stop treatment. Alternatively, they will receive a placebo injection on the same schedule plus pembrolizumab. The total treatment duration can last up to about two years. During the study, participants will be monitored for cancer progression and survival for up to about three years for progression-free survival and up to six years for other outcomes including overall response and survival. Researchers will collect tumor tissue samples for genetic and biomarker analyses and assess safety by tracking adverse events and treatment discontinuations. The study involves regular visits for treatments and assessments throughout the treatment period and follow-up monitoring.

Age: 18Years +All GendersPhase 2
38 locations

1-10 of 1,593

1